Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Treatment Burden of Myopic Choroidal Neovascularization
Sponsor: Policlinico Gaspare Rodolico - San Marco Catania
Summary
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue. Myopic choroidal neovascularization (mCNV) is a well-known complication of PM, occurring in 5-11% of cases and representing a main cause of visual impairment in working people under the age of 50. The management of patients affected by active mCNV have been revolutionized by the advent of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs. Patients affected by mCNV needs intravitreal injections and visits to assess the need of retreatment with assiduity. It represents a significant burden for patients, caregivers as well as medical equipe. The aim of this study is to investigate the factors associated with the number of anti-VEGF injections and hospital visits necessary to get mCNV disease stabilization and to identify predictive factors of treatment burden.
Official title: Factors Associated to Treatment Burden in Patients Affected by Myopic Choroidal Neovascularization
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2025-06-01
Completion Date
2025-12-15
Last Updated
2025-06-06
Healthy Volunteers
No
Interventions
anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
All patients underwent one intravitreal injection at baseline (0.5 mg ranibizumab or 2.0 mg aflibercept); additional intravitreal injections were administered over the follow-up period based on the above-mentioned activity signs with a pro-re-nata (PRN) treatment protocol. The patients have been followed on a monthly or bimonthly basis. The number of visits and examinations in the 12-month study period will be collected. Clinical and imaging data of the baseline examination as well as of the 12-month visit (M12) after the first intravitreal injection.
Locations (1)
Policlinico Rodolico
Catania, Italy, Italy